VivoSeq
Cardiovascular

Venous Leg Ulcers

0

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Venous Leg Ulcers is an early-stage landscape with 0 programs across 6 companies. The most active players are OcuNexus Therapeutics, Inc., TR Therapeutics, Reponex Pharmaceuticals A/S.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

OcuNexus Therapeutics, Inc.

0 programs

PreclinicalT

TR Therapeutics

0 programs

PreclinicalR

Reponex Pharmaceuticals A/S

0 programs

PreclinicalF

Factor Therapeutics Ltd.

0 programs

PreclinicalO

Oneness Biotech Co., Ltd.

0 programs

PreclinicalK

Kringle Pharma Europe AB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

21

clinical trials

Completed10 · 48%
Unknown status5 · 24%
Recruiting2 · 10%
Terminated2 · 10%
Not yet recruiting1 · 5%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

21 trials

Tissue Repair Gel in Venous Leg Ulcers (US)
Recruiting·TTR Therapeutics·Phase 3·NCT06707090·312 enrolled
Tissue Repair Gel in Venous Leg Ulcers in AU/US
Recruiting·TTR Therapeutics·Phase 3·NCT06707103·312 enrolled
Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers
Not yet recruiting·MMediWound Ltd·Phase 2·NCT06690177·45 enrolled
Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)
Completed·BBioTissue Holdings, Inc·Phase 2·NCT03818828·31 enrolled
Dose Finding Study of HP802-247 in Venous Leg Ulcers
Completed·HHealthpoint·Phase 2·NCT00852995·228 enrolled
A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)
Completed·OOcuNexus Therapeutics, Inc.·Phase 2·NCT00820196·98 enrolled
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers
Completed·XXequel Bio, Inc.·Phase 1·NCT02652572·10 enrolled
Treatment Outcome of Autologous PRP Versus Conventional Therapy Among Patients With Chronic Venous Leg Ulcers
Completed·JJinnah Postgraduate Medical Centre·Phase 1·NCT05974982·48 enrolled
Low Dose Aspirin for Venous Leg Ulcers
Completed·UUniversity of Auckland, New Zealand·Phase 3·NCT02158806·251 enrolled
Cell Therapy for Venous Leg Ulcers Pilot Study
Completed·HHospital de Clínicas Dr. Manuel Quintela·Phase 1·NCT01750749·4 enrolled
A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers
Completed·MMediWound Ltd·Phase 2·NCT03588130·120 enrolled
A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers
Completed·OOcuNexus Therapeutics, Inc.·Phase 2·NCT01199588·300 enrolled
Clinical Trial Enzyme Application Targeting Venous Leg Ulcers
Completed·SSolasCure Limited·Phase 2·NCT04956900·43 enrolled
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
Terminated·HHealthpoint·Phase 2·NCT02154087·1 enrolled
A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.
Terminated·OOneness Biotech Co., Ltd.·Phase 4·NCT05322525·9 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)